Neurothera Labs Inc. focuses on developing cannabinoid-based drugs, particularly utilizing THC and non-psychoactive compounds. While the company boasts a strong gross margin of 74.7%, it faces significant concerns with negative EBITDA and net margins, indicating operational inefficiencies. Additionally, a low current ratio of 0.25 raises liquidity concerns, suggesting potential difficulties in meeting short-term obligations. The high gross margin juxtaposed with poor overall financial health highlights a need for improved cost management and revenue generation strategies.
Loading financial metrics...
No significant red flags identified
This company appears financially healthy on available metrics
Debt-free balance sheet with a solid cash position, providing significant financial flexibility.
Excellent liquidity with current ratio of 91.1x ensures operational stability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Based on 2026-H1 (June 30, 2026)